Skyrizi loss of exclusivity?

When Does Skyrizi Lose Patent Exclusivity?

Skyrizi is a treatment for psoriasis and psoriatic arthritis. It was developed by AbbVie and consists of risankizumab. The active ingredient is covered by a patent in the United States, granted in [1]. The company is responsible for maintaining patent protection to limit competition from generic or biosimilar formulations.

How Does Patent Exclusivity Work for Skyrizi?

AbbVie's patent protections ensure exclusivity for Skyrizi in the United States until a specified date, at which point other manufacturers can produce the active ingredient. The exact exclusivity dates are not publicly available but generally are tied to patent expiration.

Exclusivity and Biosimilars for Skyrizi

Once patent exclusivity lapses, AbbVie will no longer have control over who produces risankizumab. However, biosimilar developers require a specific approval process. Biosimilars must demonstrate that they are highly similar to the original medication, which usually includes clinical trials to prove safety and efficacy.

Impact on Patients and Skyrizi Costs

When patent exclusivity expires, biosimilar versions of risankizumab may enter the market, leading to potential price drops and increasing access for patients who currently rely on Skyrizi. It remains to be seen how AbbVie will maintain pricing and patient access to the medication as competition increases.

Regulatory Framework

Regulatory bodies around the world monitor and regulate the development and approval process for pharmaceuticals. Companies must follow established processes and demonstrate compliance with specific regulations before launching a new treatment.

Patent Expiration and Skyrizi Development

The Skyrizi patent timeline is not publicly available, but we know that patent protection typically lasts around 10-20 years, depending on various factors. This allows AbbVie time to recover the costs of researching and developing Skyrizi. However, the actual timeline may vary due to specific details of the patent agreement.

Timeline for Skyrizi Patent Expiration

The timeline for patent expiration is a key factor for AbbVie's business strategy. The company may plan to introduce improvements to maintain a competitive edge before patent protection ends.

Sources:

1. https://www.drugs.com/exclusivity/risankizumab.html

DrugPatentWatch.com: For more information on patent status and exclusivity for Skyrizi and other medications, visit www.drugs.com.